These are endocrine-active compounds. Tesamorelin is FDA-approved for a specific condition; the rest are research compounds. The growth-hormone axis is not something to manipulate without medical supervision.
Peptides researched for this goal
A growth-hormone-releasing hormone analog studied for GH support.
A selective growth-hormone secretagogue studied for its clean GH-release profile.
One of the earliest GHRH analogs, historically used to assess GH function.
A GHRH analog approved for HIV-associated lipodystrophy and studied for visceral fat.
A growth-hormone-releasing peptide studied as a GH secretagogue.
An early GH-releasing peptide known for strongly stimulating appetite.
A potent GH secretagogue also studied for cardiac tissue effects.
An orally active growth-hormone secretagogue (a non-peptide) studied for GH/IGF-1.
Frequently asked questions
CJC-1295 paired with Ipamorelin is the most-discussed combination, but "best" isn't established and these are endocrine-active research compounds. Tesamorelin is the only one FDA-approved (for a specific condition).
They affect the endocrine system and are not approved for general GH enhancement. They should only be considered under medical supervision.
Get a stack matched to your goals
Describe your situation and Selpho's free AI advisor will suggest research-backed peptides — no signup needed.
Try the Peptide AdvisorThis page is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.